Tenderwize
Zurück zur Suche

Open-house rebate agreements for Pimecrolimus

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 29, 2028 · 553 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Pimecrolimus, ATC D11AH02

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Submission route is constrained: paper originals in duplicate or email with qualified electronic signature are required...

Only pharmaceutical companies are eligible, and products must be authorized and marketable in Germany.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive open-house rebate agreements for medicinal products with active substance Pimecrolimus (ATC D11AH02).
  • Supply of authorized and marketable medicinal products in Germany under the contract terms.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Pimecrolimus (ATC D11AH02) offered by AOK Rheinland-Pfalz/Saarland. It is non-exclusive, open to interested pharmaceutical companies only, with uniform terms and no individual negotiation. The contract period runs from 01.05.2026 to 30.04.2028, with monthly entry possible during the term. No contract value is stated. Submission is by signed paper originals or by email with qualified electronic signature; electronic submission via the procurement platform is not allowed. Procurement documents are available via DTVP, but only the notice text was provided here, so the full documents were not analyzed.

Risiken

Submission route is constrained: paper originals in duplicate or email with qualified electronic signature are required...

Only pharmaceutical companies are eligible, and products must be authorized and marketable in Germany.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only authorized and marketable medicinal products in Germany may be supplied.

Eligibility

  • Only pharmaceutical companies are eligible to become contractual partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce database extract must be provided with specified information.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreements for Pimecrolimus

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Pimecrolimus (ATC D11AH02). The notice states that children’s medicines listed by BfArM under § 35(5a) SGB V are excluded. Terms are uniform for all participants; no individual negotiations. Contract start is earliest 01.05.2026, with monthly entry possible during the 24-month period. The lot information comes from structured data and notice text.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Frist

Deadline Feb 29, 2028

Vergabedetails

Veröffentlichungsdatum
15 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
178873-2026

Dokumente (1)

Ähnliche Ausschreibungen